



Insights Into Myelofibrosis (MF) January 12, 2022

Chair: Prithviraj Bose, MD

AGENDA

Time (CT)	Topic
6.00 PM – 6.15 PM (15 min)	Introduction <ul style="list-style-type: none"> • Program overview • ARS questions
6.15 PM – 7.45 PM (40-min presentation; 50-min discussion)	Current Management and Emerging Challenges in MF <ul style="list-style-type: none"> • Diagnosis and Work-up <ul style="list-style-type: none"> – Risk assessment and stratification – Prognostic genetic mutations – Symptom burden assessment/monitoring for signs of disease progression to symptomatic disease • Current therapy paradigms for MF <ul style="list-style-type: none"> – Lower-risk disease – Higher-risk disease – Impact of platelet counts on therapy • Unmet needs and emerging paradigms <ul style="list-style-type: none"> – On-treatment prognostic factors: organomegaly, thrombocytopenia (disease- and treatment-related), anemia, and transfusion-dependency – JAK2 V617F variable allelic frequency burden and the disease course <ul style="list-style-type: none"> • Proliferative MF • Cytopenic MF—unmet need for effective therapy – Pipeline approaches with targeting beyond JAK1/2 (eg, pacritinib) – Future directions • Moderated Discussion
7.45 PM – 8.00 PM (15 min)	Key Takeaways and Meeting Evaluation